R

Repligen

Bioprocessing solutions for biologics manufacturing

Bioprocessing Account Manager

Full-TimeUpdated on 10/23/2026
No salary listed
Senior, Expert
Bachelor's, Master's
Remote in China
RemoteRemote in China; up to 80% domestic travel and occasional international travel.
Sales & Account ManagementAccount Management

About the job

Requirements
  • A bachelor's degree or higher in a scientific field such as biology or biochemistry, or a similar major.
  • At least 8 years of experience in the biopharmaceutical or life science industries.
  • A strong understanding of cell culture, chromatography, and filtration; additional knowledge of upstream and downstream processing is beneficial.
  • A successful sales track record and key account management experience.
  • Strong analytical, forecasting, and management skills.
  • Strong communication and presentation skills.
  • Strong technical and business acumen.
  • Strong stakeholder management and influencing skills.
  • Ability to prioritize and work independently to achieve defined goals.
  • Ability to work effectively within global, cross-functional teams.
  • Ability and willingness to work flexible hours to accommodate client schedules.
  • Proficiency in Microsoft Office and Salesforce.com.
  • Proficiency in English listening, reading, writing, and speaking.
  • Willingness and ability to travel up to 80% domestically and occasionally internationally.
  • A proven track record of completing projects worth more than USD 5 million.
  • Ability to influence complex customer decision-making processes through strategic account management.
  • Ability to manage long sales-cycle opportunities and multifunctional customer projects.
  • A strong understanding of bioprocess manufacturing workflows from upstream to downstream operations.
Responsibilities
  • Develop sales strategies and sales plans in the assigned territory to drive growth and profitability.
  • Seek leads and opportunities to build and manage a robust sales pipeline.
  • Promote and sell upstream, downstream, and single-use products, and articulate the differentiators and value proposition of company products.
  • Contribute to market research, major customer projects, new product launches, and new product development initiatives.
  • Implement marketing plans in the assigned sales area, including organizing road shows, seminars, promotions, and developing sales collateral in coordination with the marketing team.
  • Ensure compliance with sales processes by recording and monitoring lead management, sales activities, and funnel management through Salesforce.com.
  • Establish and maintain strategic key-account relationships.
  • Collaborate closely with internal stakeholders.
  • Provide timely and accurate sales reporting and forecasting in the customer relationship management system.
  • Maintain relationships with key market infrastructure partners and identify new sales and business opportunities.
  • Represent customer and market needs to the internal organization.
  • Coordinate with Business and Market Development to share accurate and timely product, market, and competitive information.
  • Support the development of sales collateral.
  • Provide Manufacturing and QA/QC operations with timely information to support forecasting, customer complaint handling, and facility audits.
  • Conduct field sales activities, including customer visits, technical presentations, laboratory demonstrations, and quote negotiations.
  • Attend, manage, and follow up on trade show activities to generate leads.
  • Participate in or lead projects and assignments as professional development opportunities.
  • Drive strategic system and consumable opportunities involving filtration, TFF, chromatography, and single-use technologies.
  • Support customer projects involving scale-up, technology transfer, validation, and commercial manufacturing activities.
  • Build and maintain relationships with stakeholders across manufacturing, engineering, process development, procurement, and quality assurance teams.
  • Lead commercial discussions and coordination for large-scale capital equipment and strategic projects.
  • Identify competitive displacement opportunities and develop strategic account penetration plans.
Desired Qualifications
  • Experience managing major biopharmaceutical or contract development and manufacturing organization (CDMO) accounts is preferred.
  • Experience with system business, single-use technologies, and process equipment is highly preferred.
  • Experience supporting complex customer projects, CDMO environments, and capital equipment opportunities is highly valued.
  • Additional skills and understanding of upstream and downstream processing would be beneficial.

About the company

R

Repligen

View
Website

Repligen provides products and services to support biotherapeutic manufacturing. It offers filtration, chromatography systems, process analytics, fluid management, and protein solutions that help develop and produce biologics such as cell and gene therapies, mRNA, monoclonal antibodies, antibody–drug conjugates, bispecific antibodies, and fusion proteins. Its offerings are designed to fit the full bioprocess workflow—from upstream filtration and purification to downstream analytics and process control—through a portfolio of systems, consumables, and services. Repligen differentiates itself by maintaining a broad, integrated suite of bioprocessing technologies and global manufacturing support across 22 sites, enabling clients to scale from development to commercial production. The company’s goal is to advance and accelerate the manufacturing of biologics by providing reliable, end-to-end solutions that streamline development and scale-up.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1981

Get referred to Repligen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $204 million, with 13% organic growth and 55% adjusted operating growth.
  • Management raised 2026 guidance to $813-$835 million revenue and $2.03-$2.09 adjusted EPS.
  • BioLife expects $20 million year-one synergies and accretion by at least five cents.

What critics are saying

  • Repligen's BioLife deal needs approvals, or the $1.5 billion thesis breaks by Q4 2026.
  • Gene therapy headwinds, ATF issues, and Polymem hurt organic growth by roughly four points.
  • If integration stalls, Cytiva and Sartorius keep owning bioprocessing workflows and pricing power.

What makes Repligen unique

  • Repligen supplies Protein A ligands into Cytiva and MilliporeSigma OEM resin franchises.
  • Its July 2026 BioLife acquisition adds 18 approved therapies and recurring biopreservation consumables.
  • Repligen's Breda, Waltham, and Tokyo innovation centers embed it directly with customers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Health Savings Account/Flexible Spending Account

Growth & Insights and Company News

6 month growth

18%

1 year growth

29%

2 year growth

29%
Yahoo Finance
Oct 27th, 2026
Repligen swings to quarterly loss after $41.2M intangible impairment charge

Repligen, the Nasdaq-listed bioprocessing company, swung to a net loss in its latest quarter after booking a $41.2 million intangible asset impairment charge. It had reported a profit in the prior period. Management named the write-down as a major factor behind the result. The charge is a one-off accounting hit, but it raises questions about how past acquisitions and product bets are valued. Revenue was $209.3 million for the quarter and $607.7 million for the nine months. Repligen makes technologies and systems that support biologic drug production.

Yahoo Finance
Oct 27th, 2026
Repligen posts record $209M Q3 revenue, eyes $1B in 2027 after BioLife deal

Repligen reported record third-quarter revenue of $209 million, beating its 2022 peak. Organic growth was 12.5%, led by proteins and chromatography, which offset weakness in filtration. Capital equipment orders hit a five-year high, but customers asked to move deliveries into 2027, which weighed on revenue. Filtration revenue fell 11%. China revenue grew more than 40%. The company paid $550 million in cash for BioLife, leaving a pro forma cash balance of over $300 million. It also booked a $41 million non-cash impairment on a legacy intellectual property licence. Repligen narrowed its 2026 organic growth outlook to 12%-13%. It expects 2027 revenue to top $1 billion, and BioLife to add at least $0.05 to earnings that year.

Yahoo Finance
Oct 26th, 2026
Repligen Q3 preview: analysts expect 9.6% revenue growth as shares slip 8.8%

Repligen (NASDAQ:RGEN), a biopharma manufacturing company, reports third-quarter earnings on Tuesday before market hours. Analysts expect revenue to grow 9.6% year on year, down from 21.9% in the same quarter last year. Last quarter, Repligen beat revenue estimates with $204.1 million, up 11.9%. Analysts have largely held their estimates over the past 30 days. Peers offer some clues. Medpace's revenue rose 8.5%, meeting expectations, while Thermo Fisher's rose 9.1%, beating estimates by 1.4%. Both stocks fell about 1.6% afterwards. Repligen shares are down 8.8% over the past month, trading at $177.03. The average analyst price target is $201.45.

Business Insider
Oct 17th, 2026
Repligen (RGEN) receives a Buy from J.P. Morgan.

Repligen (RGEN) receives a Buy from J.P. Morgan. Oct. 17, 2026, 08:55 AM J.P. Morgan analyst Casey Woodring maintained a Buy rating on Repligen yesterday and set a price target of $200.00. The company's shares closed yesterday at $175.42. According to TipRanks, Woodring is a 5-star analyst with an average return of 13.6% and a 68.22% success rate. Woodring covers the Healthcare sector, focusing on stocks such as Illumina, Guardant Health, and Natera. Repligen has an analyst consensus of Strong Buy, with a price target consensus of $196.67, representing a 12.11% upside. In a report released on October 7, Barclays also maintained a Buy rating on the stock with a $225.00 price target. Based on Repligen's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $204.13 million and a net profit of $5.01 million. In comparison, last year the company earned a revenue of $182.37 million and had a net profit of $14.87 million Read More on RGEN:

Scientist Live
Sep 10th, 2026
Analysis of the 2026 chromatography consumables market.

Analysis of the 2026 chromatography consumables market. Published: 10 September 2026 The global chromatography consumables market is projected to increase from US$6.0 billion in 2026 to US$9.7 billion by 2035, representing a compound annual growth rate of approximately 5.6% during the forecast period. Market expansion is being supported by rising pharmaceutical and biopharmaceutical research and development, increased biologics manufacturing, stricter testing requirements, and sustained investment in laboratory automation. This is according to a new report called 'Chromatography Consumables Market by Product, Chromatography Technique, End User, and Geographical Regions - Trends and Forecast Till 2035' from ResearchAndMarkets.com. Chromatography consumables market growth and trends Pharmaceutical and biotechnology companies account for a significant share of chromatography consumables demand. Columns, syringe filters, tubes, fittings, vials, well plates, purification resins, and related products are used throughout drug discovery, process development, analytical validation, quality control, lot release, stability testing, and commercial manufacturing. Growth in advanced biologics, biosimilars, vaccines, cell therapies, and gene therapies is accelerating demand for modality-specific purification products. Suppliers are introducing specialised affinity and ion-exchange resins for adeno-associated virus vectors, plasmid DNA, and other advanced therapy workflows. Repligen Corporation, for example, has introduced AVIPure affinity resins and HiPerT anion-exchange resins for gene therapy and viral vector purification applications. Food safety, environmental monitoring, clinical diagnostics, forensic analysis, petrochemical testing, and chemical analysis are also expanding the addressable market. Regulatory testing for pesticide residues, mycotoxins, allergens, adulterants, heavy metals, persistent pollutants, and volatile compounds requires recurring purchases of application-specific columns, high-purity solvents, filtration products, and solid-phase extraction cartridges. Key market drivers * Increasing pharmaceutical and biopharmaceutical R&D expenditure * Expansion of biologics, vaccine, biosimilar, cell therapy, and gene therapy pipelines * Growing adoption of automated and high-throughput analytical workflows * Stricter food safety, environmental monitoring, and quality-control regulations * Rising demand for pre-packed and single-use chromatography columns * Development of bio-inert, micro-volume, and solvent-efficient consumables Digitalisation is creating additional opportunities across the chromatography consumables market. Radio-frequency identification and other tracking technologies are increasingly being integrated into columns and guard cartridges to monitor injection counts, pressure history, and solvent volumes. These capabilities can strengthen workflow control, improve consumable management, and reduce unplanned analytical failures. Market challenges High product costs remain a barrier, particularly for smaller laboratories, academic institutions, and facilities operating under restricted budgets. Specialty columns and purification resins can require frequent replacement, increasing total operating expenditure. The industry also relies on a concentrated global supply base for silica, specialty polymers, and high-purity solvents, exposing manufacturers and end users to supply disruptions, price volatility, and longer procurement cycles. Chromatography consumables market segment highlights By product, columns are expected to account for the largest market share through 2035. Their central role in analytical and purification workflows, combined with recurring replacement requirements, supports a durable revenue base. The syringe filters segment is forecast to record a higher growth rate as demand increases for sample cleanup, sterile filtration, and pre-injection processing. By technique, liquid chromatography is projected to retain the largest share of the global chromatography consumables market. Its broad use in pharmaceutical, food and beverage, environmental, and biopharmaceutical laboratories continues to support demand for columns, solvents, filters, fittings, and sample-handling products. Gas chromatography is anticipated to expand at a comparatively higher rate, supported by environmental testing, petrochemical analysis, food safety programs, and forensic applications. Pharmaceutical and biotechnology companies are expected to remain the leading end-user segment. Environmental agencies are projected to experience faster growth as monitoring programs expand for drinking water, soil, air pollutants, and regulated contaminant classes such as per- and polyfluoroalkyl substances. Regional market outlook North America is expected to maintain the largest share of global chromatography consumables market revenue. The region benefits from a strong biopharmaceutical research ecosystem, extensive regulated manufacturing capacity, established laboratory infrastructure, and stringent quality standards across the United States and Canada. Asia-Pacific is forecast to register a higher CAGR through 2035. Growth is being supported by biopharmaceutical capacity expansion, regulatory modernisation, increased contract development and manufacturing activity, and continued investment in food, environmental, clinical, and academic testing laboratories across China, India, Japan, South Korea, and Australia. Competitive landscape Leading companies operating in the chromatography consumables market include: * Agilent Technologies * Bio-Rad Laboratories * JASCO * Millipore Sigma * Revvity * Sartorius * Shimadzu Scientific Instruments * Thermo Fisher Scientific Competitive strategies increasingly focus on specialised purification chemistries, pre-packed columns, single-use products, digitally enabled consumables, strategic acquisitions, and complete workflow portfolios. Recent industry activity also reflects consolidation in specialty downstream processing and sample preparation. Companies are pursuing acquisitions and portfolio investments to strengthen intellectual property, expand chromatography resin capabilities, and provide more integrated analytical and bioprocessing solutions. Market research coverage The chromatography consumables market report provides revenue forecasts and opportunity assessments by product, chromatography technique, end user, and geography. Product coverage includes columns, syringe filters, tubes and fittings, vials and well plates, and other consumables. Technique coverage includes liquid chromatography, gas chromatography, thin-layer chromatography, and additional chromatographic methods. The research evaluates market drivers, restraints, opportunities, competitive forces, patents, partnerships, investments, and recent industry developments. It also includes company profiles and insights from technical directors, product managers, analytical chemists, consultants, research scientists, and other industry stakeholders. Strategic value The report is designed to support manufacturers, distributors, channel partners, investors, and business development teams evaluating opportunities in the global chromatography consumables market. It provides data-driven insight into customer demand, competitive positioning, regional expansion, emerging applications, and high-growth market segments. Purchasers also receive analytical data packs, supporting insights, report customisation options, a research-team walkthrough, and an eligible complimentary update for reports more than six months old.